

# Advancing *in vivo* CAR technology based on recombinant proteins for the treatment of CD19 B-cell blood cancers

Kangwon National University



ONCOLOGY

Lead

|                          |                                                                                                                                                                                                                                                                                                 |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Product Type             | rProtein                                                                                                                                                                                                                                                                                        |
| Indication               | CD19 positive B cell malignancies                                                                                                                                                                                                                                                               |
| Target                   | CD19                                                                                                                                                                                                                                                                                            |
| MoA(Mechanism of Action) | CD19-iCAR protein is intended to bind T/NK cells, anchored at the immune-cell membrane and generate a non-genetic CAR-effectors in the body ( <i>in vivo</i> CAR)                                                                                                                               |
| Competitiveness          | CD19-iCAR is positioned as a first-in-class protein based non-genetic <i>in vivo</i> CAR approach. Against gene-based <i>in vivo</i> CAR approaches, the proposal emphasizes non-genetic delivery, predictable dosing, and simpler CMC/regulatory handling as recombinant protein therapeutics. |
| Development Stage        | Lead                                                                                                                                                                                                                                                                                            |
| Route of Administration  | Systemic Administration                                                                                                                                                                                                                                                                         |

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*